All In Biotech

Drug Trial Radar · NCT05547503

Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers

A Double-blind, Placebo-controlled, Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Oral AFA-281 (Phase I Part 1) and Multiple Ascending Doses of Oral AFA-281 (Phase I Part 2) in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Apr 11, 2023

Primary completion

Dec 4, 2024

Study completion May 14, 2025

Sponsor

Lead sponsor
Afasci IncIndustry
Sponsor type
Industry
Collaborators
Cognitive Research Corporation
First posted
Sep 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase I Part 1 (single ascending dose): Double-blind dosing will occur in healthy volunteers in 4 cohorts of 8 subjects each. Six subjects in each cohort will be randomized to receive AFA-281 and 2 subjects will be randomized to receive the matching placebo. At the end of the Part 1 study is to evaluate the safety and tolerability of AFA-281. Following completion of each cohort, bioanalytical analyses will be conducted to evaluate the pharmacokinetic profile. Phase I Part 2 (multiple dose for 14 days): Pending the results from Part 1, healthy volunteers will be administered AFA-281 for 14 to 21 consecutive days in 3 cohorts. At scheduled intervals after dosing, and at the end of the cohort's study period to evaluate the safety and tolerability and the pharmacokinetic profile of AFA-281.

Conditions

  • Pain, Neuropathic
  • Pain, Inflammatory

Interventions

  • AFA-281Drug

    Part 1: AFA-281 will be administered as a single dose at 4 dose levels (TBD) Part 2: AFA-281 will be administered twice daily for 14 - 21 days at 3 dose levels (TBD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-Related Adverse EventsTime frame: Predose and Up to 72 hours after dose
  2. Heart rateTime frame: Predose and Up to 72 hours after dose
  3. Body temperatureTime frame: Predose and Up to 72 hours after dose
  4. Blood PressureTime frame: Predose and Up to 72 hours after dose
  5. Electrocardiogram (ECG)Time frame: Pre-dose and up to 72 hours after dose
  6. Blood chemistryTime frame: Pre-dose and up to 72 hours after dose
  7. HematologyTime frame: Pre-dose and up to 72 hours after dose
  8. CoagulationTime frame: Pre-dose and up to 72 hours after dose
  9. UrinalysisTime frame: Pre-dose and up to 72 hours after dose
  10. Blood maximum plasma concentration (Cmax) of the study drugTime frame: Pre-dose and up to 72 hours after dose
  11. Blood study drug half-life (t1/2)Time frame: Pre-dose and up to 72 hours after dose
  12. Area under the plasma concentration versus time curve (AUC) of the study drugTime frame: Pre-dose and up to 72 hours after dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CenExcel CNS

    Los Alamitos, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.